Financial Results
Q3/2024 Results
Simplification and focus drives sustained performance – Outlook upgraded
- Group organic revenue growth of 9%1,2 to €5.3 billion driven by a strong Kabi performance and good organic growth at Helios.
- Strong bottom-line traction with Group EBIT2 increase in constant currency of 9%3 to €552 million and EPS growth of 7%2,3,4.
- Group outlook for fiscal 2024 upgraded; Organic revenue growth1,2 is now expected to grow between 6% to 8% (previous: between 4% to 7%) and EBIT growth2 in constant currency is now targeted to be in the 8 to 11% range (previous: between 6% to 10%).
- Group-wide cost and productivity savings ahead of plan with target for FY/24 already achieved YTD.
- Excellent operating cash flow resulting from focused cash management.
Selected Key Figures Q3/2024
GROUP REVENUE
€ 5305 m
+ 9% 1
Q3/23: €4,967 m
GROUP EBIT 2
€ 552 m
+9% 3
Q3/23: €509 m
NET INCOME 2, 4, 5
€ 312 m
+7% 3
Q3/23: €292 m
EPS 2, 4, 5
€ 0.55
+7% 3
Q3/23: €0.51
1 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
2 Before special items
3 Growth rate at constant currency (cc) and adjusted for Argentina hyperinflation
4 Net income attributable to shareholders of Fresenius SE & Co. KGaA
5 Excluding Fresenius Medical Care
Revenue by business segment
| € in millions | Q3/24 | Q3/23 | Growth at actual rates | Growth at constant rates | Organic growth1 | Acquisitions/Divestitures | % of total revenue |
|---|---|---|---|---|---|---|---|
Fresenius Kabi | 2,114 | 2,021 | 5% | 10% | 11% | -1% | 40% |
Fresenius Helios | 3,082 | 2,863 | 8% | 8% | 8% | 0% | 58% |
Total | 5,303 | 4,967 | 7% | 9% | 9% | 0% | 100%2 |
-
1 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
2 Remaining 2% Corporate/Other revenue
Before special items